



**Manchester
Metropolitan
University**

Noro, Fabrizia, Gianfagna, Francesco, Gialluisi, Alessandro, De Curtis, Amalia, Di Castelnuovo, Augusto, Napoleone, Emanuela, Cerletti, Chiara, Donati, Maria Benedetta, de Gaetano, Giovanni, Hoylaerts, Marc F, Iacoviello, Licia, Izzi, Benedetta and Moli-family study Investigators (2019) ZBTB12 DNA methylation is associated with coagulation- and inflammation-related blood cell parameters: findings from the Moli-family cohort. *Clinical Epigenetics*, 11 (1). p. 74. ISSN 1868-7083

Downloaded from: <https://e-space.mmu.ac.uk/628018/>

Version: Published Version

Publisher: BioMed Central

DOI: <https://doi.org/10.1186/s13148-019-0665-6>

Usage rights: Creative Commons: Attribution 4.0

Please cite the published version

<https://e-space.mmu.ac.uk>

RESEARCH

Open Access



ZBTB12 DNA methylation is associated with coagulation- and inflammation-related blood cell parameters: findings from the Moli-family cohort

Fabrizia Noro¹, Francesco Gianfagna^{2,3}, Alessandro Gialluisi¹, Amalia De Curtis¹, Augusto Di Castelnuovo³, Emanuela Napoleone⁵, Chiara Cerletti¹, Maria Benedetta Donati¹, Giovanni de Gaetano¹, Marc F. Hoylaerts⁴, Licia Iacoviello^{1,2*}, Benedetta Izzi¹ and on behalf of the Moli-family study Investigators

Abstract

Background: Zinc finger and BTB domain-containing protein 12 (ZBTB12) is a predicted transcription factor with potential role in hematopoietic development. Recent evidence linked low methylation level of ZBTB12 exon1 to myocardial infarction (MI) risk. However, the role of ZBTB12 in the pathogenesis of MI and cardiovascular disease in general is not yet clarified. We investigated the relation between ZBTB12 methylation and several blood parameters related to cardio-cerebrovascular risk in an Italian family-based cohort.

Results: ZBTB12 methylation was analyzed on white blood cells from the Moli-family cohort using the Sequenom EpiTYPER MassARRAY (Agena). A total of 13 CpG Sequenom units were analyzed in the small CpG island located in the only translated ZBTB12 exon. Principal component analysis (PCA) was performed to identify groups of CpG units with similar methylation estimates. Linear mixed effect regressions showed a positive association between methylation of ZBTB12 Factor 2 (including CpG units 8, 9–10, 16, 21) and TNF- α stimulated procoagulant activity, a measure of procoagulant and inflammatory potential of blood cells. In addition, we also found a negative association between methylation of ZBTB12 Factor 1 (mainly characterized by CpG units 1, 3–4, 5, 11, and 26) and white blood cell and granulocyte counts. An in silico prediction analysis identified granulopoiesis- and hematopoiesis-specific transcription factors to potentially bind DNA sequences encompassing CpG1, CpG3–4, and CpG11.

Conclusions: ZBTB12 hypomethylation is linked to shorter TNF- α stimulated whole blood coagulation time and increased WBC and granulocyte counts, further elucidating the possible link between ZBTB12 methylation and cardiovascular disease risk.

Keywords: DNA methylation, Granulocyte counts, White blood cell counts, Whole blood coagulation time, Zinc fingers, Cardiovascular risk

* Correspondence: licia.iacoviello@neuromed.it; licia.iacoviello@moli-sani.org

¹Department of Epidemiology and Prevention, IRCCS NEUROMED, Pozzilli, IS, Italy

²Department of Medicine and Surgery, University of Insubria, Varese, Italy

Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Background

The *zinc finger and BTB domain-containing protein 12* (*ZBTB12*) is a predicted transcription factor belonging to the big family of methyl-CpG-binding proteins (MBPs) [1]. *ZBTB12* consists of four C-terminal C2H2/Krüppel-type zinc finger domains predicted to bind to DNA, and an N-terminal BTB (broad-complex, tram-track, and bric-a-brac) domain for protein–protein interactions [2]. *ZBTB* proteins are described to play a role in hematopoietic development, differentiation and lineage fate determination [3], and malignant transformation [4]. Guarrera and colleagues [5] performed a genome-wide DNA methylation analysis in white blood cells (WBC) from two European cohorts and identified a region in *ZBTB12* as the top differentially methylated genomic region in patients with myocardial infarction (MI) [5]. *ZBTB12* hypomethylation was associated with MI risk, and the association was more pronounced in cases with shorter time to disease [5]. Despite *ZBTB12* is expressed in most human tissues (Human Protein Atlas available from www.proteinatlas.org), its function and possible role in MI pathogenesis are still unknown.

In light of *ZBTB12*'s potential role in hematopoiesis and MI risk, we investigated the association between *ZBTB12* methylation patterns in the Moli-family cohort [6] and different blood cell parameters related to coagulation, inflammation, and cardiovascular disease (CVD) risk including whole blood clotting time, platelet–leukocyte mixed aggregates, and blood cell counts, previously suggested as CVD risk factors [6–10].

Results

ZBTB12 is located on chromosome 6 and contains two CpG islands, both covering the only translated exon of the gene (EXON1, Fig. 1). Mean and standard deviation (SD) of methylation levels at the 13 *ZBTB12* units studied are shown in Table 1. To identify possible connections among the *ZBTB12* methylation units studied in the Moli-family cohort, we run a correlation analysis among all CpG units included in the study (Fig. 2). Since we found significant CpG unit inter-correlations, we conducted a principal component analysis (PCA) aiming at identifying common underlying components that


Table 1 Distribution of *ZBTB12* factor loadings (*N* = 342) and specific CpG unit methylation in the Moli-family cohort


| CpG number | Factor loading | | Methylation levels | | |
|------------|----------------|-------------|--------------------|------|------|
| | Factor 1 | Factor 2 | <i>N</i> | Mean | SD |
| 3–4 | <i>0.83</i> | 0.03 | 440 | 0.37 | 0.09 |
| 26 | <i>0.80</i> | − 0.04 | 453 | 0.37 | 0.10 |
| 1 | <i>0.74</i> | 0.16 | 458 | 0.35 | 0.10 |
| 11 | <i>0.70</i> | 0.20 | 415 | 0.28 | 0.14 |
| 5 | <i>0.58</i> | 0.19 | 419 | 0.11 | 0.09 |
| 27 | <i>0.56</i> | 0.10 | 408 | 0.43 | 0.14 |
| 18–19–20 | <i>0.47</i> | 0.12 | 411 | 0.71 | 0.12 |
| 6 | <i>0.43</i> | − 0.15 | 450 | 0.64 | 0.20 |
| 9–10 | 0.27 | <i>0.89</i> | 457 | 0.24 | 0.07 |
| 21 | 0.23 | <i>0.83</i> | 458 | 0.09 | 0.06 |
| 16 | 0.01 | <i>0.80</i> | 458 | 0.17 | 0.10 |
| 8 | 0.26 | <i>0.78</i> | 457 | 0.06 | 0.03 |
| 7 | 0.11 | − 0.34 | 421 | 0.63 | 0.14 |

PCA resulted in the identification of two factors with eigenvalue > 1. Factor loadings of the main sites for each factor are highlighted in *italics*

could explain the largest part of methylation variability shared across units. Two main methylation factors emerged with PCA (Table 1), explaining a large part of gene methylation variance (86.1%). Factor 1 was characterized by high positive loadings of CpGs 3–4, 26, 1, 11, 5, 27, 18–20, and 6, and Factor 2 showed high loadings of CpGs 9–10, 21, 16, and 8 (Table 1). We first studied the association of *ZBTB12* methylation factors with a number of classical CVD risk factors, including physical activity, smoke, hypertension, dyslipidemia, obesity, diabetes, and alcohol consumption. General characteristics and CVD risk factor distribution in the analyzed cohort are reported in Table 2. By studying the association between *ZBTB12* methylation and these environmental factors, we observed that alcohol intake greater than 15 g/day ($\beta = -0.415$, $p = 0.0024$, pFDR significant) was associated with Factor 2, while obesity ($\beta = 0.40$, $p = 0.0053$) and leisure-time physical activity (-0.155 , $p = 0.0050$) were associated with Factor 1 only with nominal significance (Table 2).

Then, we used linear mixed effect regression models to evaluate associations between *ZBTB12* methylation





and different blood parameters related to coagulation, inflammation, and CVD risk, namely unstimulated and TNF α -stimulated coagulation time (along with the resulting unstimulated–stimulated delta difference), platelet–monocyte and platelet–PMN aggregates, and blood cell counts (see Table 3). We did this through a double approach, by investigating association with methylation factors and with single CpG units. Because among the environmental variables associated with *ZBTB12* methylation, only alcohol and obesity were associated with blood cell counts at $p < 0.1$ (data not shown), these variables were additionally included in the model as covariates to study the association between *ZBTB12* methylation and blood cell counts (Tables 3 and 5).

We found a significant association between Factor 2 and TNF- α -stimulated whole blood clotting time, with 16.0% increase in SD of clotting time for an increase of 1 SD in

Factor 2 ($\beta = 0.160$, $p = 0.0047$; Table 3). The linear association between TNF- α -stimulated whole blood clotting time and Factor 2 was evident below the median (-0.15) of adherence to the factor (Fig. 3a). Subjects with low methylation levels at factor units showed a coagulation time reduced by about half a minute (Δ -time in Fig. 3a) compared to those with higher methylation levels. The results did not significantly change when blood cell counts were added to the models as covariates.

Among blood cell count association results, WBC were associated with Factor 1, an association mainly driven by granulocytes (Table 3). In a similar fashion as for Factor 2, this association was evident at adherence to Factor 1 below the median (-0.05), after which a plateau was reached (Fig. 3b).

A detailed single CpG unit analysis supported the associations observed with methylation factors, reporting a

Table 2 Association between *ZBTB12* methylation factors and CVD risk factors

| CVD risk factors | Associations between methylation factors and phenotypes | | | | | | | | | |
|--|---|----------|-------|----------|---------|-------|-----------------|----------|-------|----------------|
| | Factor 1 | | | | | | | Factor 2 | | |
| | <i>N</i> | Mean | SD | <i>N</i> | Beta | SE | <i>p</i> -value | Beta | SE | <i>p</i> value |
| Age (years) | 458 | 42.80 | 18.83 | 342 | 0.005 | 0.003 | 0.696 | − 0.001 | 0.003 | 0.806 |
| Leisure-time physical activity (MET/day) | 449 | 2.31 | 1.07 | 336 | − 0.111 | 0.052 | 0.035 | − 0.066 | 0.052 | 0.206 |
| | <i>N</i> | <i>n</i> | % | | Delta | SD | <i>p</i> value | Delta | SD | <i>p</i> value |
| Males | 458 | 236 | 53.7% | 342 | 0.031 | 0.105 | 0.768 | − 0.148 | 0.104 | 0.157 |
| Ever smokers | 458 | 212 | 46.2% | 342 | 0.182 | 0.115 | 0.113 | − 0.024 | 0.114 | 0.831 |
| Alcohol (> 15 g/day) | 422 | 93 | 22.0% | 319 | − 0.013 | 0.139 | 0.925 | − 0.415 | 0.135 | 0.0024* |
| Hypertension | 456 | 162 | 35.5% | 341 | 0.040 | 0.146 | 0.783 | − 0.186 | 0.144 | 0.198 |
| Dyslipidemia | 456 | 191 | 41.9% | 341 | 0.179 | 0.116 | 0.125 | − 0.150 | 0.115 | 0.193 |
| Obesity | 456 | 93 | 20.4% | 341 | 0.298 | 0.145 | 0.041 | 0.165 | 0.145 | 0.256 |
| Diabetes | 458 | 26 | 5.7% | 342 | 0.159 | 0.232 | 0.495 | − 0.003 | 0.230 | 0.988 |

Model adjusted by age and gender as fixed effects and family stratification as a random effect. Significant *p* values are shown in *italics*
MET metabolic equivalent of task
*pFDR significant (alcohol, pFDR = 0.043)

Table 3 Association between *ZBTB12* methylation factors and blood cell parameters

| | N | Mean | SD | Associations between methylation factors and phenotypes | | | | | | |
|--|-----|--------|-------|---|----------|-------|---------|----------|-------|---------|
| | | | | N | Factor 1 | | | Factor 2 | | |
| | | | | | Beta | SE | p | Beta | SE | p |
| Functions | | | | | | | | | | |
| Coagulation time (sec.) | 417 | 395.51 | 77.66 | 313 | − 0.007 | 0.052 | 0.891 | 0.051 | 0.052 | 0.333 |
| TNFα-stim. coagulation time (sec.) | 417 | 350.90 | 72.89 | 313 | − 0.021 | 0.056 | 0.709 | 0.160 | 0.056 | 0.0047* |
| Delta coag. time (basal-TNF) (sec.) | 417 | 44.60 | 56.53 | 313 | − 0.034 | 0.052 | 0.510 | 0.145 | 0.052 | 0.0053* |
| Platelet-monocyte aggr. (%) | 450 | 7.81 | 9.06 | 337 | 0.107 | 0.045 | 0.019 | 0.005 | 0.046 | 0.912 |
| Platelet-PMN aggr. (%) | 449 | 4.43 | 4.97 | 336 | 0.032 | 0.049 | 0.509 | − 0.016 | 0.050 | 0.743 |
| Blood cell count | | | | | | | | | | |
| White blood cells (10 ⁹ /L) | 458 | 6.38 | 1.48 | 318 | − 0.161 | 0.054 | 0.0032* | − 0.036 | 0.055 | 0.509 |
| Lymphocyte (10 ⁹ /L) | 458 | 2.00 | 0.58 | 318 | − 0.065 | 0.056 | 0.254 | − 0.063 | 0.057 | 0.271 |
| Monocytes (10 ⁹ /L) | 458 | 0.42 | 0.17 | 318 | − 0.076 | 0.052 | 0.147 | 0.023 | 0.053 | 0.661 |
| Granulocytes (10 ⁹ /L) | 458 | 3.96 | 1.17 | 318 | − 0.158 | 0.056 | 0.0048* | − 0.032 | 0.056 | 0.567 |
| Platelets (10 ⁹ /L) | 458 | 253.82 | 61.84 | 318 | − 0.050 | 0.052 | 0.335 | − 0.044 | 0.053 | 0.407 |
| Red blood cells (10 ⁹ /L) | 458 | 4.91 | 0.51 | 318 | − 0.046 | 0.049 | 0.352 | 0.003 | 0.049 | 0.945 |

Model adjusted by age, gender, and smoking as fixed effects and family stratification as a random effect; additional covariates were added to the model and were associated to both methylation factors and phenotypes (for blood cell counts, alcohol and obesity). Standardized values of phenotypes and methylation are reported (beta values reported as standard deviation units). *Delta coag. time* is obtained by the difference between unstimulated and TNF α -stimulated coagulation time. Significant *p* values are shown in italics

*pFDR significant




Fig. 3 Whole blood clotting times and white blood cell counts by Factor methylation levels. **a** Whole blood clotting times by Factor 2 methylation levels: basal (blue, solid line) and TNF- α -stimulated (red, dashed line) whole blood coagulation times and their difference (Delta = basal minus stimulated; green, dash-dot line). **b** Count of white blood cell (WBC) populations by Factor 1 methylation levels: WBC (blue, solid line) and sub-populations of granulocytes (red, short-dashed line), lymphocytes (green, dot-dashed line), and monocyte (brown, long-dashed line). A local regression with a scatterplot smoothing method that automatically determines the optimal smoothing parameter was used (PROC SGPLOT with LOESS statement in SAS). Local regression method implies that statistical power decreases at extreme *x* values (larger confidence intervals)

Table 4 Association between *ZBTB12* CpG-specific methylation and blood cell functional parameters

| Factor n. | CpG n. | Coagulation time | | | TNF α -stim. coagulation time | | | Delta coag. time (basal-TNF) | | | Platelet-monocyte aggregates | | | Platelet-PMN aggregates | | |
|-----------|----------------|------------------|-------|--------------|--------------------------------------|-------|----------------|------------------------------|-------|--------------|------------------------------|-------|--------------|-------------------------|-------|----------|
| | | Beta | SE | <i>p</i> | Beta | SE | <i>p</i> | Beta | SE | <i>p</i> | Beta | SE | <i>p</i> | Beta | SE | <i>p</i> |
| F1 | 3–4 | 0.018 | 0.045 | 0.690 | –0.019 | 0.050 | 0.711 | –0.040 | 0.049 | 0.411 | 0.074 | 0.039 | 0.061 | 0.006 | 0.043 | 0.898 |
| | 26 | –0.007 | 0.044 | 0.877 | –0.052 | 0.049 | 0.286 | –0.062 | 0.048 | 0.201 | 0.097 | 0.039 | <i>0.013</i> | –0.003 | 0.043 | 0.942 |
| | 1 | 0.023 | 0.045 | 0.608 | 0.038 | 0.049 | 0.447 | –0.002 | 0.048 | 0.974 | 0.055 | 0.039 | 0.164 | –0.023 | 0.043 | 0.602 |
| | 11 | 0.109 | 0.046 | <i>0.018</i> | 0.074 | 0.051 | 0.148 | –0.063 | 0.051 | 0.218 | 0.016 | 0.041 | 0.703 | –0.016 | 0.046 | 0.735 |
| | 5 | –0.031 | 0.046 | 0.501 | 0.013 | 0.050 | 0.798 | 0.066 | 0.049 | 0.179 | 0.068 | 0.042 | 0.102 | 0.067 | 0.046 | 0.142 |
| | 27 | –0.040 | 0.047 | 0.402 | –0.017 | 0.052 | 0.743 | 0.020 | 0.052 | 0.704 | 0.087 | 0.042 | <i>0.040</i> | 0.041 | 0.046 | 0.366 |
| | 18–20 | 0.033 | 0.044 | 0.461 | 0.045 | 0.048 | 0.353 | –0.005 | 0.048 | 0.912 | 0.037 | 0.039 | 0.342 | 0.030 | 0.044 | 0.496 |
| | 6 | –0.043 | 0.044 | 0.331 | –0.063 | 0.048 | 0.191 | –0.004 | 0.047 | 0.932 | 0.026 | 0.039 | 0.502 | –0.052 | 0.043 | 0.227 |
| F2 | 9–10 | 0.104 | 0.044 | <i>0.018</i> | 0.154 | 0.048 | <i>0.002</i> * | 0.052 | 0.048 | 0.274 | 0.028 | 0.039 | 0.478 | 0.003 | 0.043 | 0.951 |
| | 21 | 0.030 | 0.046 | 0.505 | 0.045 | 0.050 | 0.368 | 0.014 | 0.049 | 0.771 | 0.036 | 0.040 | 0.369 | –0.008 | 0.044 | 0.863 |
| | 16 | 0.052 | 0.043 | 0.224 | 0.134 | 0.047 | <i>0.005</i> * | 0.106 | 0.046 | <i>0.023</i> | –0.012 | 0.038 | 0.757 | –0.010 | 0.043 | 0.820 |
| | 8 | 0.075 | 0.044 | 0.091 | 0.126 | 0.048 | <i>0.010</i> * | 0.061 | 0.047 | 0.197 | 0.031 | 0.040 | 0.438 | 0.019 | 0.044 | 0.669 |
| | 7 [§] | –0.008 | 0.046 | 0.859 | –0.069 | 0.050 | 0.169 | –0.086 | 0.046 | 0.062 | –0.050 | 0.041 | 0.230 | –0.039 | 0.044 | 0.380 |

Model adjusted by age, gender, and smoking as fixed effects and family stratification as a random effect; additional covariates were added to the model and were associated to both methylation factors and phenotypes (for blood cell counts, alcohol, and obesity). Standardized values of phenotypes and methylation are reported (beta values reported as standard deviation units). Significant *p* values are shown in italics

*pFDR significant

[§]Factor loading for both Factor 1 and 2 lower than 0.40

significant positive association (pFDR < 0.05) between Factor 2 single CpG units (CpG8, 9–10, and 16) and TNF- α -stimulated whole blood clotting time (Table 4). When adjusting these associations for blood cell counts, the results did not change.

Furthermore, we observed significant inverse association between Factor 1 single CpG units and different blood cell counts, including WBC (with

CpG1, 3–4, 5, 26, and 11; $p \leq 0.018$) and granulocytes counts (with CpG1, 3–4, 5, 26, and 27; $p \leq 0.007$) (Table 5).

DNA methylation changes at even only one CpG site can affect transcription factor (TF) binding to the DNA, influencing gene expression. Therefore, we searched for TF putative binding sites encompassing the WBC significantly associated *ZBTB12* CpG sites. We found several TFs


Table 5 Association between *ZBTB12* CpG-specific methylation and blood cell counts

| Factor no. | CpG no. | White blood cells | | | Lymphocytes | | | Monocytes | | | Granulocytes | | | Platelets | | | Red blood cells | | |
|------------|----------------|-------------------|-------|----------------|-------------|-------|--------------|-----------|-------|----------|--------------|-------|-----------------|-----------|-------|--------------|-----------------|-------|--------------|
| | | Beta | SE | <i>p</i> | Beta | SE | <i>p</i> | Beta | SE | <i>p</i> | Beta | SE | <i>p</i> | Beta | SE | <i>p</i> | Beta | SE | <i>p</i> |
| F1 | 3–4 | –0.110 | 0.046 | <i>0.018</i> * | 0.007 | 0.047 | 0.879 | 0.002 | 0.043 | 0.972 | –0.143 | 0.048 | <i>0.003</i> * | –0.030 | 0.043 | 0.492 | 0.033 | 0.040 | 0.409 |
| | 26 | –0.139 | 0.045 | <i>0.002</i> * | –0.011 | 0.047 | 0.809 | –0.049 | 0.042 | 0.253 | –0.166 | 0.046 | <i>0.0004</i> * | –0.086 | 0.042 | <i>0.042</i> | –0.003 | 0.039 | 0.942 |
| | 1 | –0.115 | 0.046 | <i>0.013</i> * | –0.009 | 0.048 | 0.854 | 0.015 | 0.044 | 0.736 | –0.143 | 0.048 | <i>0.003</i> * | –0.062 | 0.044 | 0.166 | –0.036 | 0.040 | 0.373 |
| | 11 | –0.120 | 0.050 | <i>0.016</i> * | –0.098 | 0.052 | 0.059 | –0.018 | 0.049 | 0.710 | –0.101 | 0.051 | 0.050 | 0.007 | 0.047 | 0.885 | 0.004 | 0.044 | 0.936 |
| | 5 | –0.116 | 0.048 | <i>0.016</i> * | 0.039 | 0.050 | 0.434 | –0.056 | 0.046 | 0.219 | –0.151 | 0.050 | <i>0.003</i> * | –0.037 | 0.045 | 0.406 | –0.003 | 0.042 | 0.947 |
| | 27 | –0.109 | 0.048 | <i>0.023</i> | –0.002 | 0.050 | 0.967 | –0.007 | 0.046 | 0.884 | –0.134 | 0.050 | <i>0.007</i> * | –0.012 | 0.046 | 0.801 | –0.015 | 0.043 | 0.728 |
| | 18–20 | –0.012 | 0.048 | 0.808 | –0.130 | 0.049 | <i>0.009</i> | –0.059 | 0.045 | 0.190 | 0.053 | 0.049 | 0.281 | 0.008 | 0.045 | 0.866 | –0.076 | 0.042 | 0.073 |
| | 6 | 0.006 | 0.047 | 0.903 | 0.020 | 0.048 | 0.672 | –0.031 | 0.044 | 0.485 | 0.002 | 0.048 | 0.960 | 0.042 | 0.044 | 0.341 | 0.089 | 0.040 | <i>0.027</i> |
| F2 | 9–10 | –0.049 | 0.046 | 0.291 | –0.026 | 0.048 | 0.591 | 0.027 | 0.044 | 0.540 | –0.058 | 0.048 | 0.230 | –0.036 | 0.044 | 0.413 | –0.006 | 0.040 | 0.880 |
| | 21 | –0.014 | 0.047 | 0.766 | 0.009 | 0.049 | 0.856 | 0.011 | 0.045 | 0.814 | –0.029 | 0.048 | 0.551 | –0.050 | 0.045 | 0.264 | –0.034 | 0.040 | 0.400 |
| | 16 | –0.015 | 0.046 | 0.746 | –0.048 | 0.047 | 0.314 | 0.034 | 0.043 | 0.434 | –0.006 | 0.048 | 0.901 | –0.011 | 0.043 | 0.793 | 0.031 | 0.040 | 0.437 |
| | 8 | –0.055 | 0.047 | 0.234 | –0.015 | 0.048 | 0.763 | 0.029 | 0.044 | 0.510 | –0.071 | 0.048 | 0.142 | –0.004 | 0.045 | 0.928 | –0.059 | 0.040 | 0.145 |
| | 7 [§] | –0.056 | 0.048 | 0.238 | –0.076 | 0.049 | 0.119 | –0.067 | 0.044 | 0.128 | –0.028 | 0.049 | 0.576 | –0.013 | 0.046 | 0.784 | 0.004 | 0.041 | 0.920 |

Model adjusted by age, gender, and smoking as fixed effects, and family stratification as a random effect; additional covariates were added to the model and were associated to both methylation factors and phenotypes (for blood cell counts, alcohol, and obesity). Standardized values of phenotypes and methylation are reported (beta values reported as standard deviation units). Significant *p* values are shown in italics

*pFDR significant

[§]Factor loading for both Factor 1 and 2 lower than 0.40



predicted to bind CpG units 1, 3–4, 5, 11, 26, and 27 (Additional file 1). Interestingly, among the putative transcription factors identified, we observed a high predictive binding score of PAX-5 and p53 on both CpG units 1 and 3–4, and of E2F-1 on both CpG units 3–4 and 11 (Fig. 4).

Discussion

Our study shows that the *ZBTB12* methylation profile is associated with whole blood coagulation time after TNF- α stimulation and with WBC and granulocyte counts.

ZBTB12 is a highly conserved gene among species, but still poorly investigated. Recently, its hypomethylation has been associated with MI risk, in two European cohorts by Guarrera and colleagues [5]. In our study, we identified common linking patterns of the 13 *ZBTB12* CpG units investigated (Factor 1 and Factor 2 in Table 1) that independently affect different CVD-related blood cell characteristics.

On the one hand, *ZBTB12* Factor 2 was significantly associated with both the TNF- α -stimulated procoagulant activity and the time difference between unstimulated and TNF- α -stimulated procoagulant activity, independently on blood cell counts. Reflecting blood procoagulant activity potential, the coagulation time is calculated as the time taken for recalcified blood to clot and is considered to be a sensitive marker of the potential clot formation and CVD risk [7]. This is because thrombus formation depends upon the procoagulant and inflammatory potential of blood cells, including monocytes, granulocytes, platelets, endothelial cells, and plasma vesicles [11]. TNF- α is specifically implicated in inflammation-related thrombosis by promoting extrinsic coagulation activation. This is achieved by inducing tissue factor expression on the leukocyte surface, downregulating natural anticoagulants (protein C and heparin–

antithrombin pathways) as well as thrombomodulin and the endothelial protein C receptor, while increasing platelet production, thereby enhancing thrombin formation [12].

On the other hand, *ZBTB12* Factor 1 hypomethylation is associated with higher total WBC and granulocyte counts already having been associated with higher CVD risk and mortality [8, 9]. Neutrophils, the largest part of granulocyte population, are also involved in the formation of neutrophil extracellular traps (NETs), known to play a role in thrombus formation [13]. Both white and red blood cells contribute to the activation of coagulation and to thrombin formation also through the action of their extracellular vesicles (EVs), additional mediators of inflammation [14]. These results suggest a second potential role of *ZBTB12* in affecting myelopoiesis.

ZBTB12 expression could be regulated through the binding of myelopoiesis and hematopoiesis-specific TFs, also influenced by DNA methylation [15]. In line with this hypothesis, our data on *ZBTB12* TF binding site prediction showed that the *ZBTB12* CpG units 1, 3–4, and 11 are predicted to be bound by PAX-5 and p53 (units 1 and 3–4), known to be involved in hematopoiesis and B cell differentiation [16] and cell cycle arrest required for terminal myelopoiesis [17, 18], and by E2F-1 (units 3–4 and 11), with a pro-apoptotic role in hematopoiesis [19] (Fig. 4). Supporting this hypothesis, *ZBTB12* expression in blood cells is indeed variable across cell types and differentiation stages (data from the BLUEPRINT Consortium [20], <https://blueprint.haem.cam.ac.uk/mRNA>). *ZBTB12*, as all ZBTB proteins, could also in turn bind myelopoiesis-related genes, acting as a TF, thanks to its predicted ability of binding methylcytosine (5mC) and/or oxidized methylcytosine (oxi-mCs)-rich DNA sequences, target sequences for Zn fingers [3]. DNA methylation is a known predictor of cell specification throughout the human hematopoietic lineage [21], and other ZBTB proteins

are already described to be specifically involved in granulopoiesis [22] and myeloid development in general [23].

Conclusion

Our data indicate that *ZBTB12* hypomethylation (of both Factor 1 and Factor 2) that was previously associated with MI risk [5] is linked to shorter TNF- α -stimulated whole blood coagulation time and increased WBC and granulocyte counts. This hitherto undescribed association with blood parameters, known to be implicated in CVD [7–9], further support the hypothesis of a link between *ZBTB12* methylation and CVD risk. Future experimental studies should focus on the specific molecular mechanism(s) of this zinc finger protein in blood cell proliferation, maturation, and activity and its possible role in human cardiovascular disorders.

Methods

Study population

Moli-family is a family-based study which aimed to investigate the role of inflammation-mediated activation of hemostasis in CVD risk [6]. A total of 754 subjects (≥ 15 years old) were recruited from 54 extended pedigrees (23 families with and 31 control families without personal or familial history of early-onset MI). All participants were relatives of index subjects enrolled in the Moli-sani cohort study [24], which recruited 24,325 subjects randomly selected from civil registries of the Molise Region, Southern Italy, between 2005 and 2010.

In all subjects, a complete medical history and information about smoking and alcohol-drinking habits were obtained via a structured questionnaire. Height, body weight, and blood pressure were measured as described in [6, 25, 26].

Blood sample collection and blood functional tests

Biochemical analyses were performed in the centralized Moli-sani laboratory. Blood samples were obtained between 07:00 and 09:00 from participants who had fasted overnight and had refrained from smoking for at least 6 h. Hematological cytometric analyses were performed by the same cell counter (Coulter HMX, Beckman Coulter, IL Milan, Italy), within 1 h from venipuncture. Platelet-leukocyte conjugates, platelet P-selectin, leukocyte CD11b, and L-selectin expression were measured in whole blood for the Moli-family participants, as described [27].

Whole blood procoagulant activity was measured by the coagulation time. Whole blood was incubated for 2 h at 37 °C with or without tumor necrosis factor (TNF)- α (100 ng/ml). The optimal agonist concentration was previously selected on the basis of dose-response curves (not shown). At the end of incubation, whole blood

coagulation time (i.e., the time taken for recalcified blood to clot) was assessed by a one-stage clotting time. Briefly, 200- μ L whole blood were mixed with 100 μ L 25 mM CaCl_2 , and the time to clot formation was recorded (seconds) [28].

DNA extraction and methylation analysis

Buffy coats of peripheral blood cells were isolated from whole blood samples collected in sodium citrate EDTA tubes and centrifuged at 3000 rpm for 20 min at RT. DNA extraction was done using a silica matrix-based method as described [29]. Of the 754 Moli-family participants, 623 had good quality DNA samples to perform the methylation analysis. We measured *ZBTB12* methylation using the Sequenom EpiTYPER MassARRAY (Agena) platform [15]. Details of the *ZBTB12* region studied (chr6: 31899847-31900326, GRCh38/hg38 Assembly) are reported by Guarrera and colleagues [5]. Bisulfite treatment was conducted on 1 μ g of genomic DNA using the MethylDetector kit (Active Motif) as described [15]. All PCR amplifications were performed in duplicate. For the CpG-specific analysis, data were discarded when the duplicate measurements had a standard deviation (SD) $\geq 5\%$ [15, 30, 31]. Sequenom peaks with reference intensity > 2 and overlapping units were excluded from the analysis [15, 30, 31]. To exclude possible intra-plate differences, a sample of K562 DNA was carried on in each plate as an internal control.

Of the 20 CpG units included in the *ZBTB12* region studied [5] (CGI1 in Fig. 1), we excluded the ones having more than 15% of missing values in the Moli-family cohort, leading to a total of 13 CpG (Table 1).

Statistical analysis

Statistical analyses were performed using SAS/STAT software (Version 9.4 for Windows©2009. SAS Institute Inc. and SAS are registered trademarks of SAS Institute Inc., Cary, NC, USA). Mean and SD were computed for continuous variables and frequencies for categorical variables. All continuous variables, including methylation data, were also transformed to z-scores (mean = 0; SD = 1).

Correlation analysis among *ZBTB12* CpG units was initially conducted to discover the architecture of relationships among the methylation units studied. Then, a PCA was conducted with the aim of identifying common underlying patterns that could explain the largest part of common variance in methylation across units. PCA was conducted including the 342 individuals having all the 13 *ZBTB12* CpG units successfully measured. Criteria for factor selection were eigenvalue > 1.0 as revealed by the scree test, and the interpretability of the final solution. This resulted in the identification of two main factors (Table 1), which were transformed by the

orthogonal varimax rotation to keep independent latent variables for subsequent analysis [32], and then standardized. We characterized the factors using the *ZBTB12* methylation sites with an absolute factor loading > 0.40. Each subject received a factor score, calculated by summing the observed methylation site values, each weighted by factor loadings.

We first studied the association between *ZBTB12* methylation factors and CVD risk factors (unstimulated and TNF α -stimulated coagulation time along with the resulting unstimulated–stimulated delta difference, platelet–monocyte and platelet–PMN aggregates, and blood cell counts) (Table 2), in linear mixed effect regression models adjusted for age, sex (fixed effects), and family stratification (random effect) to account for the family structure of the Moli-family cohort.

Similarly, linear mixed effect regression models were used to assess the relation of blood parameters related to CVD risk, with *ZBTB12* methylation patterns (Factor 1 and Factor 2) and single CpG units. Age, gender, smoking (never-, ex-, and current smokers), and variables significantly associated with both methylation factors and specific phenotypes at $p < 0.1$ were treated as fixed effects, while family stratification was treated as a random effect. A false discovery rate (FDR) method (Benjamini–Hochberg) was used to adjust p values for multiple testing. A p value (pFDR) < 0.05 was considered as statistically significant. DNA methylation is cell specific and might be different among the leukocyte sub-populations, leading to false positive findings when an appropriate correction for cell count is not performed [33]. *ZBTB12* was not identified as a locus with leukocyte-specific DNA methylation levels [33]. Therefore, in our analysis, we did not correct for WBC counts.

Prediction of *ZBTB12* DNA binding factors

To detect potential regulatory effects of methylation at the CpG sites investigated, we searched for *ZBTB12* putative binding sites, by using the PROMO software [34]. More specifically, we included in our query the regions surrounding each of the CpG sites which were found as associated with blood cell parameters in previous analyses. This allows to construct weight matrices from known binding sites extracted from the TRANSFAC DNA binding site library (version 8.3), which contains the largest available collection of DNA binding sites in eukaryotes [35, 36]. The full *ZBTB12* region analyzed in the methylation study (chr6: 31899847–31900326, GRCh38/hg38 Assembly) was used as DNA sequence bait in the search. The prediction was made by focusing only on the human species and transcription factors, setting the minimum sequence similarity threshold for TF binding detection to 85%.

Additional file

Additional file 1: Putative transcription factor (TF) binding analysis of the blood cell count specific CpG units. Transcription factor predicted to bind to blood cell count specific CpG units. (DOCX 13 kb)

Abbreviations

CVD: Cardiovascular disease; EVs: Extracellular vesicles; FDR: False discovery rate; MBPs: Methyl-CpG-binding proteins; MI: Myocardial infarction; NETs: Neutrophil extracellular traps; PCA: Principal component analysis; SD: Standard deviation; TF: Transcription factor; TNF: Tumor necrosis factor; WBC: White blood cells; *ZBTB12*: Zinc finger and BTB domain-containing protein 12

Acknowledgements

Moli-Family Study Collaborators:

Principal investigator: Licia Iacoviello (IRCCS Neuromed, Pozzilli, and University of Insubria, Varese, Italy)

Study coordination: Branislav Vohnout (Slovak Medical University, Bratislava, Slovakia)

Scientific Committee: Marcello Arca ("Sapienza" University of Rome, Rome, Italy); Chiara Cerletti, Maria Benedetta Donati, Giovanni de Gaetano (IRCCS Neuromed, Pozzilli, Italy); Roberto Lorenzet* (Catholic University, Campobasso, Italy)

Data management and analysis: Augusto di Castelnuovo (Mediterranea Cardiocentro, Napoli, Italy); Simona Costanzo (IRCCS Neuromed, Pozzilli, Italy); Francesco Gianfagna (Mediterranea Cardiocentro, Napoli, Italy, and University of Insubria, Varese, Italy); Romina di Giuseppe (Christian-Albrechts University of Kiel, Kiel, Germany); Branislav Vohnout (Slovak Medical University, Bratislava, Slovakia)

Recruitment: Branislav Vohnout (Slovak Medical University, Bratislava, Slovakia); Antonella Cutrone (Catholic University, Campobasso, Italy)

Biobank and centralized laboratory: Amalia De Curtis (IRCCS Neuromed, Pozzilli, Italy); Sara Magnacca (Mediterranea Cardiocentro, Napoli, Italy).

Studies on platelets and leukocytes: Chiara Cerletti, Benedetta Izzi (IRCCS Neuromed, Pozzilli, Italy); Marilena Crescente (Queen Mary University of London, London, UK); Agnieszka Pampuch (Catholic University, Campobasso, Italy); Chiara Tamburrelli (Catholic University, Campobasso, Italy).

Studies on blood coagulation: Roberto Lorenzet*, Antonella Cutrone, Emanuela Napoleone, Filomena Zurlo (Catholic University, Campobasso, Italy)

Genetics laboratory: Marcello Arca, Luisa Nanni ("Sapienza" University of Rome, Rome, Italy)

*deceased

Funding

This work was supported by the "Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen" Research Grant 1508715 N, the "Programma financiering KU Leuven (PF/10/014)". The Moli-family study was supported by research grants from Telethon foundation (grant GGP04198, L.I.) and the Italian Ministry of University and Research (MIUR) (Decreto no 1588-19/11/2004). B.I. was a FWO Post-doctoral Fellow (12M2715N) and currently a Postdoctoral Fellow of the Fondazione Umberto Veronesi, Milan, Italy. F.G. was supported by the Italian Ministry of Health 2011 (Young Investigator Grant n. 167/GR-2011-02351736).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

FN designed and performed statistical analysis and wrote the manuscript. BI designed and performed the methylation experiments. FG contributed to design, performed the statistical analysis, and reviewed the manuscript. EN designed and performed the clotting time tests in the Moli-family cohort. ADeC performed the biochemical measurements of the Moli-family cohort. AG and ADiC gave advice on statistical analysis. CC, MBD, GdG, ADiC, and LI were at the origin of the conception and enrollment of the Moli-sani and Moli-family cohorts and reviewed the manuscript. MFH, LI, and BI supervised the experiments and writing of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Ethical Committee of the Catholic University of Rome. All subjects provided written informed consent, except children for whom the relative caregivers did.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Epidemiology and Prevention, IRCCS NEUROMED, Pozzilli, IS, Italy. ²Department of Medicine and Surgery, University of Insubria, Varese, Italy. ³Mediterranea Cardiocentro, Naples, Italy. ⁴Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium. ⁵Present address: Viale del Cimitero 20, 66054 Vasto, CH, Italy.

Received: 24 January 2019 Accepted: 9 April 2019

Published online: 10 May 2019

References

1. Sasai N, Nakao M, Defossez PA. Sequence-specific recognition of methylated DNA by human zinc-finger proteins. *Nucleic Acids Res*. 2010;38:5015–22. <https://doi.org/10.1093/nar/gkq280>.
2. Zhu C, Chen G, Zhao Y, Gao XM, Wang J. Regulation of the development and function of B cells by ZBTB transcription factors. *Front Immunol*. 2018;9:580. <https://doi.org/10.3389/fimmu.2018.00580>.
3. Maeda T. Regulation of hematopoietic development by ZBTB transcription factors. *Int J Hematol*. 2016;104:310–23. <https://doi.org/10.1007/s12185-016-2035-x>.
4. Bunting KL, Melnick AM. New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. *Curr Opin Immunol*. 2013;25:339–46. <https://doi.org/10.1016/j.coi.2013.05.003>.
5. Guarrera S, Fiorito G, Onland-Moret NC, Russo A, Agnoli C, Allione A, Di Gaetano C, Mattiello A, Ricceri F, Chiodini P, Polidoro S, Frasca G, Verschuren WMM, Boer JMA, Iacoviello L, van der Schouw YT, Tumino R, Vineis P, Krogh V, Panico S, et al. Gene-specific DNA methylation profiles and LINE-1 hypomethylation are associated with myocardial infarction risk. *Clin Epigenetics*. 2015;7:133. <https://doi.org/10.1186/s13148-015-0164-3>.
6. Gianfagna F, Tamburrelli C, Vohnout B, Crescente M, Izzi B, Pampuch A, De Curtis A, Di Castelnuovo A, Cutrone A, Napoleone E, Tayo B, Lorenzet R, Nanni L, Arca M, Donati MB, de Gaetano G, Cerletti C, Iacoviello L. Heritability, genetic correlation and linkage to the 9p21.3 region of mixed platelet-leukocyte conjugates in families with and without early myocardial infarction. *Nutr Metab Cardiovasc Dis*. 2013;23:684–92. <https://doi.org/10.1016/j.numecd.2012.02.008>.
7. Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. *Anesth Analg*. 2012;114:275–85. <https://doi.org/10.1213/ANE.0b013e31823a088c>.
8. Lassale C, Curtis A, Abete I, van der Schouw YT, Verschuren WMM, Lu Y, Bueno-de-Mesquita HBA. Elements of the complete blood count associated with cardiovascular disease incidence: findings from the EPIC-NL cohort study. *Sci Rep*. 2018;8:3290. <https://doi.org/10.1038/s41598-018-21661-x>.
9. Welsh C, Welsh P, Mark PB, Celis-Morales CA, Lewsey J, Gray SR, Lyall DM, Iliodromiti S, Gill JMR, Pell J, Jhund PS, Sattar N. Association of total and differential leukocyte counts with cardiovascular disease and mortality in the UK biobank. *Arterioscler Thromb Vasc Biol*. 2018;38:1415–23. <https://doi.org/10.1161/ATVBAHA.118.310945>.
10. Bonaccio M, Di Castelnuovo A, De Curtis A, Costanzo S, Persichillo M, Donati MB, Cerletti C, Iacoviello L, de Gaetano G, Moli-sani Project I. Adherence to the Mediterranean diet is associated with lower platelet and leukocyte counts: results from the Moli-sani study. *Blood*. 2014;123:3037–44. <https://doi.org/10.1182/blood-2013-12-541672>.
11. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. *Proc Natl Acad Sci U S A*. 1999;96:2311–5. <https://doi.org/10.1073/pnas.96.5.2311>.
12. Branchford BR, Carpenter SL. The role of inflammation in venous thromboembolism. *Front Pediatr*. 2018;6:142. <https://doi.org/10.3389/fped.2018.00142>.
13. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. *Blood*. 2014;123:2768–76. <https://doi.org/10.1182/blood-2013-10-463646>.
14. Hezel MEV, Nieuwland R, Bruggen RV, Juffermans NP. The ability of extracellular vesicles to induce a pro-inflammatory host response. *Int J Mol Sci*. 2017;18. <https://doi.org/10.3390/ijms18061285>.
15. Izzi B, Pistoni M, Cludts K, Akkor P, Lambrechts D, Verfaillie C, Verhamme P, Freson K, Hoylaerts MF. Allele-specific DNA methylation reinforces PEAR1 enhancer activity. *Blood*. 2016;128:1003–12. <https://doi.org/10.1182/blood-2015-11-682153>.
16. Maier H, Hagman J. Roles of EBF and Pax-5 in B lineage commitment and development. *Semin Immunol*. 2002;14:415–22.
17. Friedman AD. Transcriptional regulation of granulocyte and monocyte development. *Oncogene*. 2002;21:3377–90. <https://doi.org/10.1038/sj.onc.1205324>.
18. Glaubach T, Minella AC, Corey SJ. Cellular stress pathways in pediatric bone marrow failure syndromes: many roads lead to neutropenia. *Pediatr Res*. 2014;75:189–95. <https://doi.org/10.1038/pr.2013.197>.
19. Kikuchi J, Shimizu R, Wada T, Ando H, Nakamura M, Ozawa K, Furukawa Y. E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1. *Stem Cells*. 2007;25:2439–47. <https://doi.org/10.1634/stemcells.2007-0207>.
20. Chen L, Kostadima M, Martens JHA, Canu G, Garcia SP, Turro E, Downes K, Macaulay IC, Bielczyk-Maczynska E, Coe S, Farrow S, Poudel P, Burden F, Jansen SGB, Astle WJ, Attwood A, Bariana T, de Bono B, Breschi A, Chambers JC, et al. Transcriptional diversity during lineage commitment of human blood progenitors. *Science*. 2014;345:1251033. <https://doi.org/10.1126/science.1251033>.
21. Farlik M, Halbritter F, Muller F, Choudry FA, Ebert P, Klughammer J, Farrow S, Santoro A, Ciauro V, Mathur A, Uppal R, Stunnenberg HG, Ouwehand WH, Laurenti E, Lengauer T, Frontini M, Bock C. DNA methylation dynamics of human hematopoietic stem cell differentiation. *Cell Stem Cell*. 2016;19:808–22. <https://doi.org/10.1016/j.stem.2016.10.019>.
22. Keightley MC, Carradice DP, Layton JE, Pase L, Bertrand JY, Wittig JG, Dakic A, Badrock AP, Cole NJ, Traver D, Nutt SL, McCoe J, Buckle AM, Heath JK, Lieschke GJ. The Pu.1 target gene Zbtb11 regulates neutrophil development through its integrase-like HHCC zinc finger. *Nat Commun*. 2017;8:14911. <https://doi.org/10.1038/ncomms14911>.
23. Doulatov S, Notta F, Rice KL, Howell L, Zelent A, Licht JD, Dick JE. PLZF is a regulator of homeostatic and cytokine-induced myeloid development. *Genes Dev*. 2009;23:2076–87. <https://doi.org/10.1101/gad.1788109>.
24. Di Castelnuovo A, de Curtis A, Costanzo S, Persichillo M, Olivieri M, Zito F, Donati MB, de Gaetano G, Iacoviello L, Investigators M-SP. Association of D-dimer levels with all-cause mortality in a healthy adult population: findings from the MOLI-SANI study. *Haematologica*. 2013;98:1476–80. <https://doi.org/10.3324/haematol.2012.083410>.
25. Centritto F, Iacoviello L, di Giuseppe R, De Curtis A, Costanzo S, Zito F, Griioni S, Sieri S, Donati MB, de Gaetano G, Di Castelnuovo A, Moli-sani I. Dietary patterns, cardiovascular risk factors and C-reactive protein in a healthy Italian population. *Nutr Metab Cardiovasc Dis*. 2009;19:697–706. <https://doi.org/10.1016/j.numecd.2008.11.009>.
26. di Giuseppe R, Bonanni A, Olivieri M, Di Castelnuovo A, Donati MB, de Gaetano G, Cerletti C, Iacoviello L. Adherence to Mediterranean diet and anthropometric and metabolic parameters in an observational study in the 'Alto Molise' region: the MOLI-SAL project. *Nutr Metab Cardiovasc Dis*. 2008;18:415–21. <https://doi.org/10.1016/j.numecd.2007.05.010>.
27. Izzi B, Pampuch A, Costanzo S, Vohnout B, Iacoviello L, Cerletti C, de Gaetano G. Determinants of platelet conjugate formation with polymorphonuclear leukocytes or monocytes in whole blood. *Thromb Haemost*. 2007;98:1276–84.
28. Napoleone E, di Santo A, Peri G, Mantovani A, de Gaetano G, Donati MB, Lorenzet R. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. *J Leukoc Biol*. 2004;76:203–9. <https://doi.org/10.1189/jlb.1003528>.

29. Malferrari G, Monferini E, DeBlasio P, Diaferia G, Saltini G, Del Vecchio E, Rossi-Bernardi L, Biunno I. High-quality genomic DNA from human whole blood and mononuclear cells. *Biotechniques*. 2002;33:1228–30. <https://doi.org/10.2144/02336bm09>
30. Izzi B, Decallonne B, Devriendt K, Bouillon R, Vanderschueren D, Levtschenko E, de Zegher F, Van den Bruel A, Lambrechts D, Van Geet C, Freson K. A new approach to imprinting mutation detection in GNAS by Sequenom EpiTYPER system. *Clin Chim Acta*. 2010;411:2033–9. <https://doi.org/10.1016/j.cca.2010.08.034>.
31. Izzi B, Francois I, Labarque V, Thys C, Wittevrongel C, Devriendt K, Legius E, Van den Bruel A, D'Hooghe M, Lambrechts D, de Zegher F, Van Geet C, Freson K. Methylation defect in imprinted genes detected in patients with an Albright's hereditary osteodystrophy like phenotype and platelet Gs hypofunction. *PLoS One*. 2012;7:e38579. <https://doi.org/10.1371/journal.pone.0038579>.
32. Kim JOMC. Factor analysis: statistical method and practical issues. Thousand Oaks: Sage Publications; 1978.
33. Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlen SE, Greco D, Soderhall C, Scheynius A, Kere J. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. *PLoS One*. 2012;7:e41361. <https://doi.org/10.1371/journal.pone.0041361>.
34. Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM. PROMO: detection of known transcription regulatory elements using species-tailored searches. *Bioinformatics*. 2002;18:333–4.
35. Wingender E, Dietze P, Karas H, Knuppel R. TRANSFAC: a database on transcription factors and their DNA binding sites. *Nucleic Acids Res*. 1996;24:238–41. <https://doi.org/10.1093/nar/24.1.238>
36. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, Kloos DU, Land S, Lewicki-Potapov B, Michael H, Munch R, Reuter I, Rotert S, Saxel H, Scheer M, Thiele S, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. *Nucleic Acids Res*. 2003;31:374–8. <https://doi.org/10.1093/nar/gkg108>

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

